BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/7/2019 7:09:17 AM | Browse: 1295 | Download: 2358
 |
Received |
|
2019-03-27 02:18 |
|
Peer-Review Started |
|
2019-03-28 03:58 |
|
First Decision by Editorial Office Director |
|
2019-04-16 14:11 |
|
Return for Revision |
|
2019-04-17 03:10 |
|
Revised |
|
2019-05-29 19:07 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2019-06-25 10:53 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2019-07-03 01:12 |
|
Articles in Press |
|
2019-07-03 01:12 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-08-05 08:36 |
|
Publish the Manuscript Online |
|
2019-08-07 07:09 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Hadar Meringer, Oren Shibolet and Liat Deutsch |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Liat Deutsch, MD, Doctor, Doctor, Department of Gastroenterology and Hepatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, 6 Weizmann St., Tel-Aviv 64239, Israel. liatml@tlvmc.gov.il |
| Key Words |
Hepatocellular carcinoma; Hepatitis C virus; Direct-acting antivirals; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; |
| Core Tip |
Hepatocellular carcinoma (HCC) is a common and deadly malignancy. One of the leading risk factors for HCC occurrence is liver cirrhosis secondary to hepatitis C virus (HCV) infection. Direct-acting antiviral therapy has revolutionized HCV eradication due to high sustained virologic response rates. However, early reports argued an increased risk of HCC occurrence and recurrence. Recently, non-alcoholic fatty liver disease has become the most common liver disorder in Western countries and a major cause of HCC. We aimed to review the changes in HCC management in the face of the changing epidemiology in the post-HCV era. |
| Publish Date |
2019-08-07 07:09 |
| Citation |
Meringer H, Shibolet O, Deutsch L. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm? World J Gastroenterol 2019;25(29): 3929-3940 |
| URL |
https://www.wjgnet.com/1007-9327/full/v25/i29/3929.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v25.i29.3929 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
